Genfit SA (GNFT)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

€8.79

Buy

€8.83

arrow-down€-0.10 (-1.12%)

Prices updated at 22 Apr 2026, 16:24 CEST

Prices minimum 15 mins delay

Prices in EUR

Genfit SA is engaged in the healthcare sector. It develops therapeutic and diagnostic solutions for patient needs in metabolic, inflammatory and autoimmune diseases.

FTSE EuroFirst 300

-0.35%

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Eric Baclet

CEO

Mr. Pascal Prigent

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

192

Head office

885, Avenue Eugene Avinee

Loos

France

59120

+33 320164000

-

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Jean-Francois Mouney Chairman of the Board	0.38m
Mr. Dean Hum, PhD Chief Scientific Officer	-
Mr. Pascal Prigent Chief Executive Officer	0.41m
Mr. Jean-Christophe Marcoux Chief Corporate Affairs Officer, Head of Investor Relations and Head of ESG	-
Mr. Laurent Lannoo Corporate Secretary and Director of Legal Affairs	-
Dr. Catherine Larue, PhD Independent Director	0.05m
Ms. Anne-Helene Monsellato Independent Director	0.05m
Ms. Florence Sejourne Director	-
Ms. Carol Addy Chief Medical Officer	-
Ms. Katherine Bach Kalin, M.B.A. Independent Director	0.04m
Mr. Thomas Baetz Chief Financial Officer	-
Mr. Pascal Caisey Chief Operating Officer	-
Ms. Stefanie Magner Chief Compliance Officer and Executive Vice President, International Legal Affairs	-
Mr. Eric Baclet Vice Chairman of the Board	0.07m
Mr. Jean-Francois Tine Independent Director	0.05m
Mr. John Brozek Executive Vice President, Data and Information Technology	-
Ms. Emilie Desodt Executive Vice President, Human Resources	-
Ms. Sayah-Jeanne Sakina Executive Vice President, Research and Translational Science	-
Mr. Tom Huijbers Executive Vice President, Regulatory	-
Ms. Sandra Silvestri Director	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
CPR Asset Management	125,234
CPR Ambition France	125,234
Generali Asset Management S.p.A. Società di gestione del risparmio	114,253
Generali France PME ETI	114,253
RAM Active Investments SA	96,451

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.